Strasbourg, France & Schiphol, Netherlands, April 2, 2026, 5:45 p.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs ...
Full-year results and business updateTransgene Continues Progressto Reshape Early-Stage Cancer Treatmentthrough Individualized Neoantigen ...
Transgene has licensed the use of NEC's neoantigen prediction platform to support further development of the cancer vaccine TG4050.
Transgene and ProBioGen, a CDMO, inked a license agreement for ProBioGen’s AGE1.CR.pIX ® suspension cell line which will combine ProBioGen’s specific production technology with the manufacturing ...
Overcoming efficacy, safety, and manufacturing hurdles through innovative personalized cancer vaccine design ...
Genetically modified organisms, also known as GMOs, have been a hot topic of conversation among researchers, producers, government agencies, and the general public for decades. GMOs are banned in some ...
Transgene’s Two Innovative Platforms Progressing Well - Financial Visibility Extended Until End 2023
STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, ...
Transgene and NEC Bio ink agreement to prepare the next steps of the development of TG4050 in head and neck cancer: Strasbourg, France Monday, April 6, 2026, 17:00 Hrs [IST] Trans ...
Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results